[HTML][HTML] Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

J Yang, YA Zheng, X Gou, K Pu, Z Chen, Q Guo… - International journal of …, 2020 - Elsevier
Background An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan,
China; the epidemic is more widespread than initially estimated, with cases now confirmed …

[HTML][HTML] Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors

T Yin, Y Li, Y Ying, Z Luo - BMC infectious diseases, 2021 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) is an infectious disease
characterized by cough, fever, and fatigue and 20% of cases will develop into severe …

[PDF][PDF] Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

J Yang, Y Zheng, X Gou, K Pu, Z Chen, Q Guo… - Int J Infect …, 2020 - medicinainterna.net.pe
Background: An outbreak of Novel Coronavirus (COVID-19) in Wuhan, China, the epidemic
is more widespread than initially estimated, with cases now confirmed in multiple countries …

[HTML][HTML] Comorbidities' potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis

S Cheng, Y Zhao, F Wang, Y Chen, AC Kaminga, H Xu - Medicine, 2021 - journals.lww.com
Background: An ongoing outbreak of pneumonia associated with the severe acute
respiratory coronavirus (SARS-CoV-2) emerged in December 2019 in Wuhan, China …

[HTML][HTML] Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis

Y Zhou, Q Yang, J Chi, B Dong, W Lv, L Shen… - International Journal of …, 2020 - Elsevier
Objectives Existing findings regarding the relationship between comorbidities and the
severity of coronavirus disease 2019 (COVID-19) are inconsistent and insufficient. The aim …

COVID-19 and comorbidities: a systematic review and meta-analysis

MS Gold, D Sehayek, S Gabrielli, X Zhang… - Postgraduate …, 2020 - Taylor & Francis
ABSTRACT SARS-CoV-2 has caused a worldwide pandemic that began with an outbreak of
pneumonia cases in the Hubei province of China. Knowledge of those most at risk is integral …

Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature

KT Bajgain, S Badal, BB Bajgain, MJ Santana - American journal of …, 2021 - Elsevier
Introduction On February 11, 2020 WHO designated the name “COVID-19” for the disease
caused by “severe acute respiratory syndrome coronavirus 2”(SARS-CoV-2), a novel virus …

Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis

WH Ng, T Tipih, NA Makoah, JG Vermeulen… - MBio, 2021 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across
the globe at unprecedented speed and is showing no signs of slowing down. The outbreak …

Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: a systematic review and meta‐analysis

AK Singh, CL Gillies, R Singh, A Singh… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To estimate the prevalence of both cardiometabolic and other co‐morbidities in patients
with COVID‐19, and to estimate the increased risk of severity of disease and mortality in …

[HTML][HTML] Comorbidity and its impact on patients with COVID-19

A Sanyaolu, C Okorie, A Marinkovic, R Patidar… - SN comprehensive …, 2020 - Springer
A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), was identified in Wuhan, China, in December 2019. Since then, the virus has made its …